{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:24:15Z","timestamp":1793651055461,"version":"4.5.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s13346-020-00803-7","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T18:02:41Z","timestamp":1591725761000},"page":"1476-1494","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: evaluation using chylomicron flow blocking approach"],"prefix":"10.1007","volume":"10","author":[{"given":"Nagarjun","family":"Rangaraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravanthi Reddy","family":"Pailla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunitha","family":"Sampathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"issue":"11","key":"803_CR1","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.3109\/10428194.2013.777837","volume":"54","author":"JA Burger","year":"2013","unstructured":"Burger JA, Buggy JJ. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma. 2013;54(11):2385\u201391.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"803_CR2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3109\/1061186X.2015.1086357","volume":"24","author":"P Kokhaei","year":"2016","unstructured":"Kokhaei P, Jadidi-Niaragh F, Sotoodeh Jahromi A, Osterborg A, Mellstedt H, Hojjat-Farsangi M. Ibrutinib-a double-edge sword in cancer and autoimmune disorders. J Drug Target. 2016;24(5):373\u201385.","journal-title":"J Drug Target"},{"issue":"12","key":"803_CR3","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1517\/14656566.2015.1067302","volume":"16","author":"MR Smith","year":"2015","unstructured":"Smith MR. Ibrutinib in B lymphoid malignancies. Expert Opin Pharmacother. 2015;16(12):1879\u201387.","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"803_CR4","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1208\/s12249-018-1147-4","volume":"19","author":"Q Qiu","year":"2018","unstructured":"Qiu Q, Lu M, Li C, Luo X, Liu X, Hu L, et al. Novel self-assembled ibrutinib-phospholipid complex for potently peroral delivery of poorly soluble drugs with pH-dependent solubility. AAPS PharmSciTech. 2018;19(8):3571\u201383.","journal-title":"AAPS PharmSciTech"},{"issue":"5\u20136","key":"803_CR5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.18632\/oncoscience.310","volume":"3","author":"D Mass\u00f3-Vall\u00e9s","year":"2016","unstructured":"Mass\u00f3-Vall\u00e9s D, Jauset T, Soucek L. Ibrutinib repurposing: from B-cell malignancies to solid tumors. Oncoscience. 2016;3(5\u20136):147.","journal-title":"Oncoscience."},{"issue":"9","key":"803_CR6","doi-asserted-by":"crossref","first-page":"dju250","DOI":"10.1093\/jnci\/dju250","volume":"106","author":"EB Haura","year":"2014","unstructured":"Haura EB, Rix U. Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing. J Natl Cancer Inst. 2014;106(9):dju250.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"803_CR7","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/jphp.12550","volume":"68","author":"F Shakeel","year":"2016","unstructured":"Shakeel F, Iqbal M, Ezzeldin E. Bioavailability enhancement and pharmacokinetic profile of an anticancer drug ibrutinib by self-nanoemulsifying drug delivery system. J Pharm Pharmacol. 2016;68(6):772\u201380.","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"803_CR8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ijpharm.2015.09.014","volume":"495","author":"V Makwana","year":"2015","unstructured":"Makwana V, Jain R, Patel K, Nivsarkar M, Joshi A. Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: elucidation of mechanism of uptake using chylomicron flow blocking approach. Int J Pharm. 2015;495(1):439\u201346.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"803_CR9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijpharm.2016.10.064","volume":"516","author":"A Garg","year":"2017","unstructured":"Garg A, Bhalala K, Tomar DS. In-situ single pass intestinal permeability and pharmacokinetic study of developed Lumefantrine loaded solid lipid nanoparticles. Int J Pharm. 2017;516(1\u20132):120\u201330.","journal-title":"Int J Pharm"},{"key":"803_CR10","first-page":"547","volume":"6","author":"S Xie","year":"2011","unstructured":"Xie S, Zhu L, Dong Z, Wang Y, Wang X, Zhou W. Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles. Int J Nanomedicine. 2011;6:547.","journal-title":"Int J Nanomedicine"},{"key":"803_CR11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejpb.2016.02.012","volume":"102","author":"L Gon\u00e7alves","year":"2016","unstructured":"Gon\u00e7alves L, Maestrelli F, Mannelli LDC, Ghelardini C, Almeida A, Mura P. Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide. Eur J Pharm Biopharm. 2016;102:41\u201350.","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"803_CR12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s13346-012-0088-9","volume":"2","author":"DK Mishra","year":"2012","unstructured":"Mishra DK, Dhote V, Bhatnagar P, Mishra PK. Engineering solid lipid nanoparticles for improved drug delivery: promises and challenges of translational research. Drug Deliv Transl Res. 2012;2(4):238\u201353.","journal-title":"Drug Deliv Transl Res"},{"key":"803_CR13","first-page":"2733","volume":"8","author":"AA Khan","year":"2013","unstructured":"Khan AA, Mudassir J, Mohtar N, Darwis Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine. 2013;8:2733.","journal-title":"Int J Nanomedicine"},{"issue":"6","key":"803_CR14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.apsb.2013.10.001","volume":"3","author":"S Kalepu","year":"2013","unstructured":"Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems\u2013an overview. Acta Pharm Sin B. 2013;3(6):361\u201372.","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"803_CR15","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/03639045.2016.1275666","volume":"43","author":"M Nooli","year":"2017","unstructured":"Nooli M, Chella N, Kulhari H, Shastri NR, Sistla R. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation. Drug Dev Ind Pharm. 2017;43(4):611\u20137.","journal-title":"Drug Dev Ind Pharm"},{"key":"803_CR16","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1016\/j.xphs.2019.04.031","volume":"108","author":"X Shi","year":"2019","unstructured":"Shi X, Song S, Ding Z, Fan B, Huang W, Xu T. Improving the solubility, dissolution, and bioavailability of Ibrutinib by preparing it in a Coamorphous state with saccharin. J Pharm Sci. 2019;108:3020\u20138.","journal-title":"J Pharm Sci"},{"key":"803_CR17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2012.09.021","volume":"64","author":"W Mehnert","year":"2012","unstructured":"Mehnert W, M\u00e4der K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2012;64:83\u2013101.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"803_CR18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.15171\/apb.2015.043","volume":"5","author":"N Naseri","year":"2015","unstructured":"Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5(3):305\u201313.","journal-title":"Adv Pharm Bull"},{"key":"803_CR19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jddst.2017.06.013","volume":"42","author":"A Beloqui","year":"2017","unstructured":"Beloqui A, del Pozo-Rodr\u00edguez A, Isla A, Rodr\u00edguez-Gasc\u00f3n A, Solin\u00eds M\u00c1. Nanostructured lipid carriers as oral delivery systems for poorly soluble drugs. J Drug Deliv Sci Technol. 2017;42:144\u201354.","journal-title":"J Drug Deliv Sci Technol"},{"key":"803_CR20","first-page":"1","volume":"2014","author":"AK Sahu","year":"2014","unstructured":"Sahu AK, Kumar T, Jain V. Formulation optimization of erythromycin solid lipid nanocarrier using response surface methodology. Biomed Res Int. 2014;2014:1\u20138.","journal-title":"Biomed Res Int"},{"issue":"2","key":"803_CR21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jfda.2017.02.001","volume":"25","author":"C-H Lin","year":"2017","unstructured":"Lin C-H, Chen C-H, Lin Z-C, Fang J-Y. Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers. J Food Drug Anal. 2017;25(2):219\u201334.","journal-title":"J Food Drug Anal"},{"key":"803_CR22","first-page":"48","volume":"2","author":"M Radtke","year":"2001","unstructured":"Radtke M, M\u00fcller RH. Nanostructured lipid drug carriers. New Drugs. 2001;2:48\u201352.","journal-title":"New Drugs"},{"key":"803_CR23","doi-asserted-by":"crossref","unstructured":"M\u00fcller RH, Alexiev U, Sinambela P, Keck CM. Nanostructured lipid carriers (NLC): the second generation of solid lipid nanoparticles. Percutaneous Penetration Enhancers Chem Methods Penetration Enhancement. Springer. 2016:161\u201385.","DOI":"10.1007\/978-3-662-47862-2_11"},{"issue":"3","key":"803_CR24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s13346-016-0291-1","volume":"6","author":"U Nagaich","year":"2016","unstructured":"Nagaich U, Gulati N. Nanostructured lipid carriers (NLC) based controlled release topical gel of clobetasol propionate: design and in vivo characterization. Drug Deliv Transl Res. 2016;6(3):289\u201398.","journal-title":"Drug Deliv Transl Res"},{"issue":"8","key":"803_CR25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1208\/s12249-019-1524-7","volume":"20","author":"N Rangaraj","year":"2019","unstructured":"Rangaraj N, Pailla SR, Chowta P, Sampathi S. Fabrication of ibrutinib nanosuspension by quality by design approach: intended for enhanced oral bioavailability and diminished fast fed variability. AAPS PharmSciTech. 2019;20(8):326.","journal-title":"AAPS PharmSciTech"},{"key":"803_CR26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.colsurfb.2017.03.006","volume":"154","author":"V Kaithwas","year":"2017","unstructured":"Kaithwas V, Dora CP, Kushwah V, Jain S. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability. Colloids Surf B: Biointerfaces. 2017;154:10\u201320.","journal-title":"Colloids Surf B: Biointerfaces"},{"issue":"3","key":"803_CR27","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jare.2016.03.002","volume":"7","author":"NV Shah","year":"2016","unstructured":"Shah NV, Seth AK, Balaraman R, Aundhia CJ, Maheshwari RA, Parmar GR. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: design and in vivo study. J Adv Res. 2016;7(3):423\u201334.","journal-title":"J Adv Res"},{"issue":"1\u20132","key":"803_CR28","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijpharm.2013.12.006","volume":"461","author":"LM Negi","year":"2014","unstructured":"Negi LM, Jaggi M, Talegaonkar S. Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers. Int J Pharm. 2014;461(1\u20132):403\u201310.","journal-title":"Int J Pharm"},{"issue":"7","key":"803_CR29","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1080\/02726351.2017.1305026","volume":"36","author":"SL Patwekar","year":"2018","unstructured":"Patwekar SL, Pedewad SR, Gattani S. Development and evaluation of nanostructured lipid carriers-based gel of isotretinoin. Part Sci Technol. 2018;36(7):832\u201343.","journal-title":"Part Sci Technol"},{"issue":"2","key":"803_CR30","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3109\/21691401.2016.1160402","volume":"45","author":"J Natarajan","year":"2017","unstructured":"Natarajan J, Baskaran M, Humtsoe LC, Vadivelan R, Justin A. Enhanced brain targeting efficacy of olanzapine through solid lipid nanoparticles. Artif Cells Nanomed Biotechnol. 2017;45(2):364\u201371.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"803_CR31","first-page":"1","volume":"2017","author":"P-S Wu","year":"2017","unstructured":"Wu P-S, Lin C-H, Kuo Y-C, Lin C-C. Formulation and characterization of hydroquinone nanostructured lipid carriers by homogenization emulsification method. J Nanomater. 2017;2017:1\u20137.","journal-title":"J Nanomater"},{"issue":"10","key":"803_CR32","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1517\/17425247.2011.605120","volume":"8","author":"B Singh","year":"2011","unstructured":"Singh B, Kapil R, Nandi M, Ahuja N. Developing oral drug delivery systems using formulation by design: vital precepts, retrospect and prospects. Expert Opin Drug Deliv. 2011;8(10):1341\u201360.","journal-title":"Expert Opin Drug Deliv"},{"issue":"5","key":"803_CR33","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ajps.2014.07.005","volume":"9","author":"S Kan","year":"2014","unstructured":"Kan S, Lu J, Liu J, Wang J, Zhao Y. A quality by design (QbD) case study on enteric-coated pellets: screening of critical variables and establishment of design space at laboratory scale. Asian J Pharm Sci. 2014;9(5):268\u201378.","journal-title":"Asian J Pharm Sci"},{"issue":"6","key":"803_CR34","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/03639045.2017.1291672","volume":"43","author":"SN Politis","year":"2017","unstructured":"Politis SN, Colombo P, Colombo G, Rekkas DM. Design of experiments (DoE) in pharmaceutical development. Drug Dev Ind Pharm. 2017;43(6):889\u2013901.","journal-title":"Drug Dev Ind Pharm"},{"issue":"10","key":"803_CR35","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1002\/jps.23686","volume":"102","author":"F Yerlikaya","year":"2013","unstructured":"Yerlikaya F, Ozgen A, Vural I, Guven O, Karaagaoglu E, Khan MA, et al. Development and evaluation of paclitaxel nanoparticles using a quality-by-design approach. J Pharm Sci. 2013;102(10):3748\u201361.","journal-title":"J Pharm Sci"},{"key":"803_CR36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejps.2016.12.020","volume":"99","author":"A Kov\u00e1cs","year":"2017","unstructured":"Kov\u00e1cs A, Berk\u00f3 S, Cs\u00e1nyi E, Cs\u00f3ka I. Development of nanostructured lipid carriers containing salicyclic acid for dermal use based on the quality by design method. Eur J Pharm Sci. 2017;99:246\u201357.","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"803_CR37","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/03639045.2017.1395459","volume":"44","author":"S Beg","year":"2018","unstructured":"Beg S, Saini S, Bandopadhyay S, Katare O, Singh B. QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of olmesartan medoxomil employing multivariate statistical techniques. Drug Dev Ind Pharm. 2018;44(3):407\u201320.","journal-title":"Drug Dev Ind Pharm"},{"key":"803_CR38","doi-asserted-by":"crossref","unstructured":"Mishra V, Kesharwani P, Amin MC, Iyer A, editors. Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes. Academic Press; 2017.","DOI":"10.1016\/B978-0-12-809717-5.00013-0"},{"issue":"4","key":"803_CR39","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ajps.2016.01.001","volume":"11","author":"D Xia","year":"2016","unstructured":"Xia D, Shrestha N, van de Streek J, Mu H, Yang M. Spray drying of fenofibrate loaded nanostructured lipid carriers. Asian J Pharm Sci. 2016;11(4):507\u201315.","journal-title":"Asian J Pharm Sci"},{"issue":"9","key":"803_CR40","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1007\/s11095-015-1673-7","volume":"32","author":"B Gupta","year":"2015","unstructured":"Gupta B, Poudel BK, Tran TH, Pradhan R, Cho H-J, Jeong J-H, et al. Modulation of pharmacokinetic and cytotoxicity profile of imatinib base by employing optimized nanostructured lipid carriers. Pharm Res. 2015;32(9):2912\u201327.","journal-title":"Pharm Res"},{"issue":"5","key":"803_CR41","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ejps.2011.12.015","volume":"45","author":"S Martins","year":"2012","unstructured":"Martins S, Tho I, Souto E, Ferreira D, Brandl M. Multivariate design for the evaluation of lipid and surfactant composition effect for optimisation of lipid nanoparticles. Eur J Pharm Sci. 2012;45(5):613\u201323.","journal-title":"Eur J Pharm Sci"},{"key":"803_CR42","volume-title":"Multivariate data analysis: in practice: an introduction to multivariate data analysis and experimental design. Multivariate Data Analysis","author":"KH Esbensen","year":"2002","unstructured":"Esbensen KH, Guyot D, Westad F, Houmoller LP. Multivariate data analysis: in practice: an introduction to multivariate data analysis and experimental design. Multivariate Data Analysis; 2002."},{"issue":"1","key":"803_CR43","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.xphs.2015.10.021","volume":"105","author":"R Baumgartner","year":"2016","unstructured":"Baumgartner R, Teubl BJ, Tetyczka C, Roblegg E. Rational design and characterization of a nanosuspension for intraoral administration considering physiological conditions. J Pharm Sci. 2016;105(1):257\u201367.","journal-title":"J Pharm Sci"},{"issue":"1","key":"803_CR44","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1080\/10717544.2017.1337823","volume":"24","author":"M Elmowafy","year":"2017","unstructured":"Elmowafy M, Ibrahim HM, Ahmed MA, Shalaby K, Salama A, Hefesha H. Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks. Drug Deliv. 2017;24(1):932\u201341.","journal-title":"Drug Deliv"},{"issue":"9","key":"803_CR45","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/chromsci\/bmv050","volume":"53","author":"A Sharma","year":"2015","unstructured":"Sharma A, Jaiswal S, Shukla M, Sharma M, Chauhan PMS, Rangaraj N, et al. HPLC\u2013MS-MS method development and validation of antileishmanial agent, S010-0269, in hamster serum. J Chromatogr Sci. 2015;53(9):1542\u20138.","journal-title":"J Chromatogr Sci"},{"issue":"7","key":"803_CR46","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.3109\/10717544.2015.1037969","volume":"23","author":"MR Bhalekar","year":"2016","unstructured":"Bhalekar MR, Upadhaya PG, Madgulkar AR, Kshirsagar SJ, Dube A, Bartakke US. In-vivo bioavailability and lymphatic uptake evaluation of lipid nanoparticulates of darunavir. Drug Deliv. 2016;23(7):2581\u20136.","journal-title":"Drug Deliv"},{"issue":"4","key":"803_CR47","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ejps.2004.12.006","volume":"24","author":"A Dahan","year":"2005","unstructured":"Dahan A, Hoffman A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur J Pharm Sci. 2005;24(4):381\u20138.","journal-title":"Eur J Pharm Sci"},{"key":"803_CR48","first-page":"1049","volume":"9","author":"C Zhang","year":"2014","unstructured":"Zhang C, Peng F, Liu W, Wan J, Wan C, Xu H, et al. Nanostructured lipid carriers as a novel oral delivery system for triptolide: induced changes in pharmacokinetics profile associated with reduced toxicity in male rats. Int J Nanomedicine. 2014;9:1049.","journal-title":"Int J Nanomedicine"},{"issue":"3","key":"803_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2157-7439.1000442","volume":"8","author":"M Patel","year":"2017","unstructured":"Patel M, Sawant K. A quality by design concept on lipid based nanoformulation containing antipsychotic drug: screening design and optimization using response surface methodology. J Nanomed Nanotechnol. 2017;8(3):1\u201311.","journal-title":"J Nanomed Nanotechnol"},{"issue":"4","key":"803_CR50","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4172\/pharmaceutical-sciences.1000145","volume":"78","author":"P Chouhan","year":"2016","unstructured":"Chouhan P, Saini T. D-optimal design and development of microemulsion based transungual drug delivery formulation of ciclopirox olamine for treatment of onychomycosis. Indian J Pharm Sci. 2016;78(4):498\u2013511.","journal-title":"Indian J Pharm Sci"},{"issue":"1\u20132","key":"803_CR51","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijpharm.2016.01.080","volume":"501","author":"A Patil-Gadhe","year":"2016","unstructured":"Patil-Gadhe A, Pokharkar V. Pulmonary targeting potential of rosuvastatin loaded nanostructured lipid carrier: optimization by factorial design. Int J Pharm. 2016;501(1\u20132):199\u2013210.","journal-title":"Int J Pharm"},{"key":"803_CR52","unstructured":"Instruments M. Zetasizer nano series user manual. MAN0317. 2004;1:2004."},{"issue":"4","key":"803_CR53","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1080\/02652048.2017.1340355","volume":"34","author":"A Singh","year":"2017","unstructured":"Singh A, Neupane YR, Panda BP, Kohli K. Lipid based nanoformulation of lycopene improves oral delivery: formulation optimization, ex vivo assessment and its efficacy against breast cancer. J Microencapsul. 2017;34(4):416\u201329.","journal-title":"J Microencapsul"},{"issue":"3","key":"803_CR54","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/10837450.2013.867445","volume":"20","author":"L Mandpe","year":"2015","unstructured":"Mandpe L, Pokharkar V. Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement. Pharm Dev Technol. 2015;20(3):320\u20139.","journal-title":"Pharm Dev Technol"},{"issue":"12","key":"803_CR55","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/0892702031000121888","volume":"29","author":"Y-L Su","year":"2003","unstructured":"Su Y-L, Liu H-Z, Guo C, Wang J. Association behavior of PEO\u2013PPO\u2013PEO block copolymers in water or organic solvent observed by FTIR spectroscopy. Mol Simul. 2003;29(12):803\u20138.","journal-title":"Mol Simul"},{"issue":"41","key":"803_CR56","doi-asserted-by":"crossref","first-page":"34137","DOI":"10.1039\/C6RA02912D","volume":"6","author":"L Han","year":"2016","unstructured":"Han L, Wang T. Preparation of glycerol monostearate from glycerol carbonate and stearic acid. RSC Adv. 2016;6(41):34137\u201345.","journal-title":"RSC Adv"},{"issue":"1\u20132","key":"803_CR57","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijpharm.2011.05.044","volume":"415","author":"R Tiwari","year":"2011","unstructured":"Tiwari R, Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm. 2011;415(1\u20132):232\u201343.","journal-title":"Int J Pharm"},{"issue":"1","key":"803_CR58","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejps.2012.05.010","volume":"47","author":"S Das","year":"2012","unstructured":"Das S, Ng WK, Tan RB. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci. 2012;47(1):139\u201351.","journal-title":"Eur J Pharm Sci"},{"key":"803_CR59","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.2147\/IJN.S214883","volume":"14","author":"H Liao","year":"2019","unstructured":"Liao H, Gao Y, Lian C, Zhang Y, Wang B, Yang Y, et al. Oral absorption and lymphatic transport of baicalein following drug\u2013phospholipid complex incorporation in self-microemulsifying drug delivery systems. Int J Nanomedicine. 2019;14:7291\u2013306.","journal-title":"Int J Nanomedicine"},{"key":"803_CR60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/351693","volume":"2014","author":"A Mishra","year":"2014","unstructured":"Mishra A, Vuddanda PR, Singh S. Intestinal lymphatic delivery of praziquantel by solid lipid nanoparticles: formulation design, in vitro and in vivo studies. J Nanotechnol. 2014;2014:1\u201312.","journal-title":"J Nanotechnol"},{"issue":"1","key":"803_CR61","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/1567201812666150120153357","volume":"13","author":"A Baheti","year":"2016","unstructured":"Baheti A, Srivastava S, Sahoo D, Lowalekar R, Prasad Panda B, Kumar Padhi B, et al. Development and pharmacokinetic evaluation of industrially viable self-microemulsifying drug delivery systems (SMEDDS) for terbinafine. Curr Drug Deliv. 2016;13(1):65\u201375.","journal-title":"Curr Drug Deliv"},{"issue":"6","key":"803_CR62","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.addr.2007.09.007","volume":"60","author":"NL Trevaskis","year":"2008","unstructured":"Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008;60(6):702\u201316.","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-020-00803-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-020-00803-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-020-00803-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T02:22:22Z","timestamp":1623205342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-020-00803-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["803"],"URL":"https:\/\/doi.org\/10.1007\/s13346-020-00803-7","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"9 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All Institutional and National guidelines for the care and use of laboratory animals were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}